Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is a leader in innovative biotechnology, with a strong portfolio of clinical-stage development programs targeting a variety of diseases, and has shown strong early success in its commercial launch of YARTEMLEA for TA-TMA. Additionally, with promising pipeline candidates such as OMS1029, OMS527, and OncotoX-AML, as well as a strong balance sheet, Omeros has a positive outlook for continued growth and earnings potential. The recently announced J-code for YARTEMLEA should also improve reimbursement clarity and potentially accelerate uptake of the drug.

Bears say

Omeros is facing reimbursement friction and a lack of standardized claims processing due to the newly approved TA-TMA drug YARTEMLEA, which may negatively impact its commercial potential. Additionally, the company has a relatively small cash flow from Omidria royalties. These factors, coupled with the competitive landscape in the biotechnology industry, suggest a negative outlook for Omeros's stock.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Jun 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.